Pharmaron (03759) States New Manufacturing Collaboration Falls Within Ordinary Business Scope; No Inside Information Identified

Bulletin Express03-12

Pharmaron Beijing Co., Ltd. (Stock Code: 03759) released an announcement under Rule 13.10 of the Hong Kong Listing Rules at the request of Hong Kong Exchanges and Clearing Limited. The company confirmed that its newly reported manufacturing collaboration with the Chinese subsidiary of a leading global pharmaceutical company is being carried out in the ordinary and usual course of business.

After conducting reasonable enquiries, the board stated it is not aware of any information that must be disclosed to prevent a false market in its securities, nor is there any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance.

Shareholders and potential investors are advised to exercise caution when dealing in Pharmaron’s shares. The announcement was authorized by Chairman Dr. Lou Boliang and dated 12 March 2026.

As of the announcement date, the board comprises three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), two non-executive directors (Mr. Li Jiaqing, Ms. Wan Xuan) and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Mr. Yu Jian).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147188732?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 20:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147188732","market":"hk","top_or_hot":-1,"title":"Pharmaron (03759) States New Manufacturing Collaboration Falls Within Ordinary Business Scope; No Inside Information Identified","media":"Bulletin Express","content":"<p>Pharmaron Beijing Co., Ltd. (Stock Code: 03759) released an announcement under Rule 13.10 of the Hong Kong Listing Rules at the request of Hong Kong Exchanges and Clearing Limited. The company confirmed that its newly reported manufacturing collaboration with the Chinese subsidiary of a leading global pharmaceutical company is being carried out in the ordinary and usual course of business.</p>\n<p>After conducting reasonable enquiries, the board stated it is not aware of any information that must be disclosed to prevent a false market in its securities, nor is there any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in Pharmaron’s shares. The announcement was authorized by Chairman Dr. Lou Boliang and dated 12 March 2026.</p>\n<p>As of the announcement date, the board comprises three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), two non-executive directors (Mr. Li Jiaqing, Ms. Wan Xuan) and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Mr. Yu Jian).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharmaron (03759) States New Manufacturing Collaboration Falls Within Ordinary Business Scope; No Inside Information Identified</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharmaron (03759) States New Manufacturing Collaboration Falls Within Ordinary Business Scope; No Inside Information Identified\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-12 20:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Pharmaron Beijing Co., Ltd. (Stock Code: 03759) released an announcement under Rule 13.10 of the Hong Kong Listing Rules at the request of Hong Kong Exchanges and Clearing Limited. The company confirmed that its newly reported manufacturing collaboration with the Chinese subsidiary of a leading global pharmaceutical company is being carried out in the ordinary and usual course of business.</p>\n<p>After conducting reasonable enquiries, the board stated it is not aware of any information that must be disclosed to prevent a false market in its securities, nor is there any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in Pharmaron’s shares. The announcement was authorized by Chairman Dr. Lou Boliang and dated 12 March 2026.</p>\n<p>As of the announcement date, the board comprises three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), two non-executive directors (Mr. Li Jiaqing, Ms. Wan Xuan) and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Mr. Yu Jian).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1147188732","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147188732","pubTimestamp":1773318210,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Pharmaron Beijing Co., Ltd. (Stock Code: 03759) released an announcement under Rule 13.10 of the Hong Kong Listing Rules at the request of Hong Kong Exchanges and Clearing Limited. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"康龙化成（03759）表示，新的制造合作属于正常业务范围；并无发现内幕消息","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"Pharmaron Beijing Co., Ltd. (Stock Code: 03759) released an announcement under Rule 13.10 of the Hong Kong Listing Rules at the request of Hong Kong Exchanges and Clearing Limited. The company confirmed that its newly reported manufacturing collaboration with the Chinese subsidiary of a leading global pharmaceutical company is being carried out in the ordinary and usual course of business.\nAfter conducting reasonable enquiries, the board stated it is not aware of any information that must be disclosed to prevent a false market in its securities, nor is there any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance.\nShareholders and potential investors are advised to exercise caution when dealing in Pharmaron’s shares. The announcement was authorized by Chairman Dr. Lou Boliang and dated 12 March 2026.\nAs of the announcement date, the board comprises three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), two non-executive directors (Mr. Li Jiaqing, Ms. Wan Xuan) and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Mr. Yu Jian).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147188732","isCrawlerRequest":true}